BDX Insider Trading
BECTON DICKINSON & CO | Surgical & Medical Instruments & Apparatus
Comprehensive Trading Performance Summary
The investment history of corporate insiders at BECTON DICKINSON & CO provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Surgical & Medical Instruments & Apparatus sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-27 17:49 | 2026-03-26 | Feld Michael | Officer - EVP, Chief Revenue Officer | SELL | $156.83 | 75 | $11,762 | 21,233 | -0.4% |
| 2026-02-28 01:45 | 2026-02-26 | Feld Michael | Officer - EVP, Chief Revenue Officer | SELL | $181.84 | 75 | $13,638 | 21,308 | -0.4% |
| 2026-02-19 01:20 | 2026-02-18 | SCOTT BERTRAM L | Director | SELL | $182.61 | 953 | $174,027 | 36,763 | -2.5% |
| 2026-01-28 17:46 | 2026-01-26 | Feld Michael | Officer - EVP, CRO & Pres. Life Sciences | SELL | $202.73 | 75 | $15,205 | 16,431 | -0.5% |
| 2026-01-16 23:43 | 2026-01-15 | Garrison Michael David | Officer - EVP & Pres Med.Essntl&BioPharm | OPT+S | $207.46 | 1,610 | $334,005 | 12,095 | 0.0% |
| 2025-12-29 15:00 | 2025-12-26 | Feld Michael | Officer - EVP, CRO & Pres. Life Sciences | SELL | $196.08 | 74 | $14,510 | 16,506 | -0.4% |
| 2025-12-18 04:12 | 2025-12-17 | Garrison Michael David | Officer - EVP & Pres Med.Essntl&BioPharm | SELL | $196.03 | 629 | $123,303 | 13,105 | -4.6% |
| 2025-12-03 02:25 | 2025-12-01 | Feld Michael | Officer - EVP, CRO & Pres. Life Sciences | SELL | $193.36 | 75 | $14,502 | 16,580 | -0.5% |
| 2025-11-08 01:36 | 2025-11-07 | SCOTT BERTRAM L | Director | SELL | $176.58 | 217 | $38,318 | 35,816 | -0.6% |
| 2025-10-28 18:58 | 2025-10-27 | Feld Michael | Officer - EVP & President, Life Sciences | SELL | $186.01 | 57 | $10,603 | 8,245 | -0.7% |
| 2025-09-29 23:58 | 2025-09-26 | Feld Michael | Officer - EVP & President, Life Sciences | SELL | $181.03 | 58 | $10,500 | 8,302 | -0.7% |
| 2025-09-11 19:36 | 2025-09-10 | Fraser Claire | Director | SELL | $187.50 | 917 | $171,938 | 22,226 | -4.0% |
| 2025-08-26 22:41 | 2025-08-22 | Feld Michael | Officer - EVP & President, Life Sciences | SELL | $197.99 | 57 | $11,285 | 8,360 | -0.7% |
| 2025-08-11 23:15 | 2025-08-11 | HAYES GREGORY | Director | BUY | $191.57 | 5,250 | $1,005,743 | 6,046 | +659.5% |
| 2025-08-09 01:56 | 2025-08-08 | Fraser Claire | Director | SELL | $192.30 | 863 | $165,955 | 23,143 | -3.6% |
| 2025-07-23 00:29 | 2025-07-18 | Garrison Michael David | Officer - EVP & President, Medical | OPT+S | $180.29 | 1,185 | $213,645 | 4,887 | 0.0% |
| 2025-06-03 01:44 | 2025-06-02 | Shan David | Officer - EVP and Chief ISC Officer | SELL | $171.19 | 1,166 | $199,608 | 4,575 | -20.3% |
| 2025-04-10 20:56 | 2025-04-09 | Garrison Michael David | Officer - EVP & President, Medical | SELL | $197.28 | 479 | $94,497 | 4,887 | -8.9% |
| 2025-03-19 20:55 | 2025-03-18 | Byrd Richard | Officer - EVP & President Interventional | SELL | $230.00 | 459 | $105,570 | 6,952 | -6.2% |
| 2025-03-13 20:03 | 2025-03-12 | Byrd Richard | Officer - EVP & President Interventional | SELL | $224.91 | 1,940 | $436,325 | 7,411 | -20.7% |
| 2025-02-13 00:44 | 2025-02-12 | SCOTT BERTRAM L | Director | SELL | $227.99 | 700 | $159,593 | 36,033 | -1.9% |
| 2025-02-11 01:03 | 2025-02-10 | Henderson Jeffrey William | Director | BUY | $233.62 | 1,500 | $350,430 | 8,015 | +23.0% |
| 2025-01-22 17:19 | 2025-01-21 | Shan David | Officer - EVP and Chief ISC Officer | SELL | $240.00 | 500 | $120,000 | 5,741 | -8.0% |
| 2025-01-22 17:18 | 2025-01-21 | Neal Shana Carol | Officer - EVP and Chief People Officer | SELL | $240.00 | 787 | $188,880 | 15,414 | -4.9% |
| 2025-01-21 16:21 | 2025-01-17 | Garrison Michael David | Officer - EVP & President, Medical | SELL | $236.51 | 597 | $141,196 | 5,544 | -9.7% |
| 2025-01-10 15:11 | 2025-01-07 | Neal Shana Carol | Officer - EVP and Chief People Officer | OPT+S | $235.00 | 788 | $185,180 | 16,201 | 0.0% |
| 2024-12-20 18:18 | 2024-12-19 | Garrison Michael David | Officer - EVP & President, Medical | SELL | $223.33 | 2,838 | $633,811 | 6,141 | -31.6% |
| 2024-12-11 04:23 | 2024-12-06 | Goette Roland | Officer - EVP and President, EMEA | OPT+S | $220.76 | 5,121 | $1,130,529 | 14,217 | 0.0% |
| 2024-12-11 04:17 | 2024-12-06 | Neal Shana Carol | Officer - EVP and Chief People Officer | SELL | $220.49 | 1,000 | $220,490 | 16,989 | -5.6% |
| 2024-12-07 00:55 | 2024-12-05 | Shan David | Officer - EVP and Chief ISC Officer | SELL | $220.25 | 1,500 | $330,375 | 6,285 | -19.3% |
| 2024-06-11 20:45 | 2024-06-10 | Spoerel Thomas J | Officer - SVP,Controller&Chief Acct Off | SELL | $239.31 | 300 | $71,793 | 1,976 | -13.2% |
| 2024-05-17 02:54 | 2024-05-15 | Goette Roland | Officer - EVP and President EMEA | SELL | $236.73 | 3,300 | $781,224 | 11,308 | -22.6% |
| 2024-05-15 21:44 | 2024-05-13 | Goette Roland | Officer - EVP and President EMEA | SELL | $236.70 | 3,300 | $781,121 | 14,608 | -18.4% |
| 2024-05-01 19:59 | 2024-04-30 | Garrison Michael David | Officer - EVP & President Medical | SELL | $232.81 | 1,715 | $399,269 | 5,381 | -24.2% |
| 2024-03-15 21:19 | 2024-03-14 | Spoerel Thomas J | Officer - SVP,Controller&Chief Acct Off | SELL | $238.29 | 282 | $67,198 | 2,276 | -11.0% |
| 2023-12-13 00:31 | 2023-12-11 | Garrison Michael David | Officer - EVP & President Medical | SELL | $232.46 | 1,239 | $288,018 | 7,274 | -14.6% |
| 2023-11-30 03:27 | 2023-11-28 | Byrd Richard | Officer - EVP & President Interventional | SELL | $238.47 | 2,156 | $514,141 | 4,120 | -34.4% |
| 2023-09-06 16:32 | 2023-09-05 | Byrd Richard | Officer - EVP & President Interventional | SELL | $274.48 | 459 | $125,986 | 3,444 | -11.8% |
| 2023-08-30 15:48 | 2023-08-28 | Fraser Claire | Director | SELL | $281.66 | 848 | $238,848 | 21,608 | -3.8% |
| 2023-08-14 23:40 | 2023-08-11 | Hickey David | Officer - EVP & President, Life Sciences | OPT+S | $277.85 | 2,974 | $826,326 | 4,199 | 0.0% |
| 2023-08-09 21:41 | 2023-08-08 | Garrison Michael David | Officer - EVP & President Medical | SELL | $277.13 | 1,300 | $360,269 | 5,157 | -20.1% |
| 2023-02-07 00:06 | 2023-02-03 | Byrd Richard | Officer - EVP & President Interventional | SELL | $248.60 | 1,421 | $353,261 | 4,119 | -25.6% |
| 2022-08-17 14:21 | 2022-08-15 | Hickey David | Officer - EVP & President, Life Sciences | SELL | $265.00 | 475 | $125,875 | 3,331 | -12.5% |
| 2022-08-17 14:19 | 2022-08-15 | Polen Thomas E Jr | Director, Officer - Chairman, CEO and President | OPT+S | $265.13 | 9,500 | $2,518,735 | 28,878 | 0.0% |
| 2022-08-11 23:24 | 2022-08-08 | Khichi Samrat S. | Officer - EVP and General Counsel | OPT+S | $260.44 | 16,480 | $4,292,051 | 5,928 | 0.0% |
| 2022-08-11 23:23 | 2022-08-09 | Polen Thomas E Jr | Officer - Executive Vice President | OPT+S | $260.00 | 1,652 | $429,520 | 28,878 | 0.0% |
| 2022-06-09 17:32 | 2022-06-07 | Spoerel Thomas J | Officer - VP Controller & Chief Acct Off | OPT+S | $260.00 | 443 | $115,180 | 1,058 | 0.0% |
| 2022-05-10 22:16 | 2022-05-06 | Hickey David | Officer - EVP & President, Life Sciences | SELL | $256.00 | 475 | $121,600 | 3,806 | -11.1% |
| 2022-02-28 23:58 | 2022-02-25 | Larson Betty D | Officer - EVP HR & CHRO | OPT+S | $271.90 | 14,374 | $3,908,291 | 5,872 | 0.0% |
| 2022-02-10 18:17 | 2022-02-08 | Fraser Claire | Director | SELL | $271.70 | 841 | $228,500 | 21,556 | -3.8% |
How to Interpret $BDX Trades
Not every insider transaction in BECTON DICKINSON & CO is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $BDX shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for BDX
Insider activity data for BECTON DICKINSON & CO is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $BDX, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.